Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80
Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80
For more information on Quantum BioPharma, visit .LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / Quantum BioPharma Ltd. (QNTM) marks a significant milestone with the successful launch of unbuzzd on Amazon. This development coincides with the Company's rebranding and ticker change to QNTM. Additionally, recent ethics approval in Australia for a Phase-1 study of Lucid-MS represents a crucial advancement in the development of a novel treatment for Multiple Sclerosis.
2024年8月30日，量子生物制药股份有限公司（QNTM）在亚马逊成功推出unbuzzd，这标志着该公司的里程碑式进展。此次开发与公司的重新品牌和股票代码更改为QNTm同时进行。此外，最近在澳洲获得伦理批准进行Lucid-MS的1期研究，为多发性硬化的新型治疗的开发取得了重要进展。
We maintain our Buy-Venture rating and have adjusted our target price to $12.80 per share, reflecting confidence in Quantum BioPharma's pioneering efforts in addressing brain disorders and alcohol health. The Company's strong pipeline includes Lucid-MS, targeting progressive Multiple Sclerosis, and unbuzzd, a formulation designed to expedite alcohol metabolism. With marketing experts Kevin Harrington and Gerry David leading unbuzzd's market launch, Quantum BioPharma is positioned for substantial growth.
我们保持买入-创业公司评级，并将目标价调整为每股12.80美元，反映出对量子生物制药在大脑疾病和酒精健康领域开拓性工作的信心。该公司的强大产品线包括针对进行性多发性硬化的Lucid-MS和旨在加速酒精代谢的unbuzzd。在市场营销专家Kevin Harrington和Gerry David的带领下，unbuzzd的市场推介，使得量子生物制药处于实现巨大增长的位置。
For access to our research report on Quantum BioPharma, please click here.
要获取我们对量子生物制药的研究报告，请点击这里。
For more information on Quantum BioPharma, visit .
了解更多关于量子生物制药的信息，请访问。
For more information on Singular Research, visit .
了解更多关于Singular Research的信息，请访问。
Singular Research
Research@SingularResearch.com
818-222-6234
Singular Research
Research@SingularResearch.com
818-222-6234
SOURCE: Singular Research
来源：Singular Research